The purpose of the study is to establish the pharmacokinetic parameters of cherry juice concentrate and identify its potential to alter inflammatory markers in gout patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
10
Subjects will receive a single 60 mL oral dose of tart cherry extract.
Subjects will receive a single 120 mL oral dose of tart cherry extract.
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Highly sensitive C-reactive protein (hs-CRP)
Reduction in hs-CRP
Time frame: Maximal change in hs-CRP from baseline through study completion (during the 12 hours after a dose)
Area under the curve (AUC)
The area under the plasma anthocyanin concentration-time curve
Time frame: Through study completion (during the 12 hours after a dose)
Change in inflammatory marker expression
Fold change in mRNA expression of Nrf2
Time frame: Through study completion (during the 12 hours after a dose)
Peak plasma concentration (Cmax)
Peak plasma concentration of anthocyanins
Time frame: Through study completion (during the 12 hours after a dose)
Time to peak plasma concentration (Tmax)
Time to achieve peak plasma anthocyanin concentration
Time frame: Through study completion (during the 12 hours after a dose)
Half-life (t1/2)
Plasma anthocyanin half-life
Time frame: Through study completion (during the 12 hours after a dose)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.